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ABSTRACT
Becker Disease is an autosomal recessive version of the rare congenital disorder called Myotonia Congenita. Due to
the rarity of Becker Disease, the genetic and pathological basis of this disease have not been studied well and
possible diagnostic methods and techniques are yet to be explored. The existing method of diagnosis of such a case
is predominantly dependent on the clinical examination. More work and studies need to be done on the diagnostic
aspect of this disease to discover newer diagnostic methods for this disease, which are more reliable and speciﬁc. In
order to develop better diagnostic methods for the disease, more cases of Becker disease need to be reported, with
details of clinical and structural abnormalities. Here, we present the case report of a seven year old boy who has a
history and clinical ﬁndings suggestive of Becker disease. Identiﬁcation of this and similar cases of Becker disease
can help us better understand this disease and hopefully one day help us develop a treatment for it.
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INTRODUCTION

brief exercise.[3] Electromyogram in these
patients shows myotonic bursts.[3] Sequence coding
CLCN1 gene can help identify 95% of cases.[3]
The genetic mutations responsible for Becker disease
have been identiﬁed to occur in CLCN1 gene, which
encodes for a chloride channel in a normal muscle
membrane.[3] This gene resides on chromosome
7q35.[5] It is responsible for the formation of voltage
dependent chloride channels, which in turn control the
movement of chloride ions into and out of cells.[5] This
abnormality therefore leads to all the symptoms
mentioned above. However, as one particular study
suggests that there can be as many as 130 different
mutations in the CLCN1 gene that are responsible for
this condition, this diversity in mutations could be the
reason why no two cases of Becker disease present in
the exact same manner.[6] Hence it is essential to
determine the most common mutations and then to
investigate the association of those mutations to their
particular clinical presentations. In order to achieve
this goal more studies need to be conducted after
receiving samples from new conﬁrmed cases of
Becker Disease.

Myotonia Congenita is a rare genetic disease and it
affects 1 in 100,000 individuals.[1] Its symptoms begin
to appear in early childhood and are characterized by
defects in the skeletal muscle membrane which leads
to delayed muscle relaxation, stiffness and weakness
of the muscles. It has two subtypes, an autosomal
dominant type (Thomsen Disease) and an autosomal
recessive type (Becker disease).[2] The symptoms are
more severe in the recessive form of this disease than
the dominant form, where the transient weakness and
stiffness of the muscle is more severe especially after
prolonged periods of rest.[3] These patient also suffer
from painless muscle stiffness, which can be relieved
by activity (a method known as the warm-up
phenomenon).[4] Moreover, these individuals have
muscular hypertrophy, specially in the limbs, which
gives them an athletic look.[3] The diagnosis of Becker
disease is dependent on clinical symptoms and signs
like muscle stiffness, delayed muscle relaxation,
difﬁculty swallowing and alleviation of stiffness after
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CASE PRESENTATION
Here we present the case of a 7 year old boy who
presented to Aga Khan University Hospital, Karachi
Pakistan, in 2016, with complains of difﬁculty in walking
and weakness of muscles, speciﬁcally in the lower
limbs. His symptoms were ﬁrst notice by the father,
who stated that the patient has had walking difﬁculties
since he was 5 years old. On inquiring, it was reported
that the patient suffered from episodes of muscle
stiffness after prolonged episodes of rest and he was
unable to walk in a straight line.
On examination, the patient appeared to be restless
and weak. He had weakness of the proximal muscles
of hips and thighs bilaterally. No muscle wasting, no
hypertonia and no atonia was observed. However, the
pathognomonic hypertrophy of calf muscle seen in
patients of myotonia congenita was also observed in
this patient. Eye examination revealed that he was also
hyperopic.
Electromyography studies showed diffuse myotonia in
all muscles examined in the upper and lower
extremities. Evaluation of voluntary motor unit action
potentials was hampered by the presence of profound
myotonia. There was no deﬁnite evidence of
myopathy. Blood tests showed that Vitamin D levels
were 20.3ng/ml.
Based on patient history, clinical examination and
electromyography test, the patient was diagnosed to
be suffering from Becker disease. The parents were
educated about this debilitating disease. Due to the
non-availability of any signiﬁcantly effective treatment,
the patient was advised to get regular physiotherapy
and prescribed Vitamin D supplements.

determine the extent of this disease. A genetic
counselor and neurologist should be taken on board to
decide how progressed the disease is and what
treatment regimen should be used. [ 3 ] A few
pharmacological treatments are being tested for
Myotonia Congenita. A randomized double blinded trial
showed that mexiletine reduced muscle stiffness in 59
patients with Myotonia and 34 patients out of these
suffered from Myotonia Congenita.[9] It has also been
suggested that other compounds, such as quinine,
dantrolene, acetazolamide, carbamezapine or
phenytoin,[10] can be tried to reduce the symptoms.
However, looking at the symptoms of this condition
anesthetic agents and depolarizing muscle relaxants
should be used with care.[3] One study also reported
that beta-antagonist propranolol worsen the
symptoms of Myotonia Congenita, hence it should be
avoided.
We have reported the ﬁrst case of Becker disease (an
autosomal recessive form of Myotonia Cogenita) from
Pakistan. This is a rare disease that should be reported
so that more research can be conducted on its genetic
basis and for the discovery of its treatment.

DISCUSSION
Myotonia Congenita, a musculoskeletal disorder, was
ﬁrst identiﬁed with seminal studies by Bryant, Lipicky
and colleagues in 1960.[6] It was in the 1990s, when the
ﬁrst CLCN1 gene mutations were discovered and
along with it the autosomal dominant and recessive
components of this disease were identiﬁed.[7] CLCN1
gene in the body is responsible for normal production
of proteins that which controls the chloride channels in
the skeletal muscle ﬁber, which then assist in normal
muscle contraction and relaxation.[8] Mutations in this
gene hence leads to alteration in the chloride
channels, which in turn reduces the movement of ions
across the membrane.[9] It is believed that mutations in
the CLCN1 gene are responsible for both autosomal
recessive (Becker disease) and dominant versions
(Thomsen disease) of Myotonia Congenita. In fact one
study has identiﬁed as many as 130 mutations in the
CLCN1 gene. [ 6 ] Hence the precise mutations
responsible for Becker and Thomsen diseases are yet
to be discovered.
In order to treat this condition it is important to
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